Australia’s Telix Pharmaceuticals Ltd. is advancing a potential challenger to Novartis plc’s dominant prostate cancer radioligand therapy, Pluvicto (lutetium [177Lu] vipivotide tetraxetan), after reporting that the safety lead-in portion of its global phase III Prostact trial met its primary objectives.
Twelve years on from the World Health Organization formally raising the alarm, antimicrobial resistance continues to grow, and despite numerous public and private incentives and initiatives, the pipeline of antibiotics in development is thinner than ever.
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Accord, Asieris, Claritas, Drug Farm, Foresee, Glenmark, Nxera, Hua Medicine, Innocare, Innovent, Meiji, Pepgen, Pharmaessentia, Protagonist, Sanofi, Sciwind, Sumitomo, Takeda.
Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Bcworld, Beam, Bio Palette, Celltype, Congruence, Daiichi Sankyo, Gaia, Grünenthal, GSK, Immunis, Ono, Rapport, Rapt, Senhwa, Shanghai Jeyou, Sinopia, Takeda, Tenacia, Toray.
GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion.
In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.
U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations.
RSS
